key: cord-1005121-6oican5y authors: Furukawa, Yoshiki; Ando, Miki; Azusawa, Yoko; Kinoshita, Shintaro; Harada, Sakiko; Ochiai, Tomonori; Honda, Tadahiro; Sugimoto, Kazuya; Tabe, Yoko; Komatsu, Norio; Ando, Jun title: Persistent immune thrombocytopaenic purpura associated with SARS‐CoV‐2 infection date: 2021-05-04 journal: EJHaem DOI: 10.1002/jha2.201 sha: 24d57a93f466a56e474bff8696b58bf7031eb643 doc_id: 1005121 cord_uid: 6oican5y nan We describe evolution of persistent immune thrombocytopaenic purpura (ITP) from acute ITP in a young woman with clinically otherwise inapparent severe acute respiratory syndrome -coronavirus 2 (SARS-CoV-2) infection (COVID-19); her development of ITP was matter for an earlier report. [1] ITP is an acquired disease in which thrombocytopaenia results from autoantibodies against platelet antigens. Approximately 10% of patients with acute ITP develop persistent (lasting 3-12 months) or chronic (>12 months) ITP. [2] Infections with viruses like Epstein-Barr virus and cytomegalovirus can trigger acute ITP. [3] Many instances of acute ITP associated with COVID-19 are described [1, [4] [5] [6] . Instances of persistent or chronic ITP associated with COVID-19 have not been reported. A previously well 30-year-old woman sought dental care for new-onset gingival bleeding in August 2020. A markedly decreased platelet count (3 × 10 9 /L) was found. She was referred to our hospital. On admission, her gums bore coagulated blood and her extremities prominent purpural and petechial lesions ( Figure 1A ). She denied medication. A platelet count was very low (4 × 10 9 /L; 2018, 164 × 10 9 /L) with a high increase in reticulated platelet count (28.6%, expected < 2.0%). Platelet-associated IgG was elevated at 559 ng/10 7 platelets (expected < 46 ng/10 7 Bone-marrow examination showed markedly increased numbers of megakaryocytes (264 × 10 6 /L), without dysplasia ( Figure 1B ). Computed tomography identified no splenomegaly and unexpectedly found bilateral ground-glass lower-lobe lung opacity; the patient was afebrile, and chest roentgenograms had been assessed as without abnormality. Real-time polymerase chain reaction (RT-PCR) testing for SARS-CoV-2, using saliva, accordingly was performed 2 days in a row, in both without detecting evidence of infection. Acute ITP was diagnosed, and intravenous immunoglobulin therapy (IVIG), 400 mg/kg, was initiated. Corticosteroids were not used because of possible pneumonia. On the fourth day of IVIG, her platelet count had increased to 38 × 10 9 /L. Nasopharyngeal RT-PCR testing detected SARS-CoV-2 sequences. Haemorrhagic disease responded to IVIG. The patient was discharged home on hospital day 10 [1] . She attended clinic monthly in follow-up. In October 2020, her platelet count had recovered (190 × 10 9 /L); however, it gradually fell again (97 × 10 9 , 68 × 10 9 , 30 × 10 9 /L: January, February, March 2021, respectively). Anti-SARS-CoV-2 immunoassays of serum detected anti-SARS-CoV-2 IgG-but not IgM-class antibody. Autoantibodies and evidence of infection again were absent (Table 1) , and bone-marrow examination findings were like those before (increase in megakaryocyte numbers at 51 × 10 6 /L without dysplasia [ Figure 1C ]). Persistent ITP following acute ITP associated with COVID-19 was diagnosed. As her platelet count is steady at >30 × 10 9 /L ( Figure 1D Mild thrombocytopaenia has been observed in approximately 5%-10% of patients with COVID-19 infection [7] . Implicated factors and mechanisms include cytokine storm, direct infection of haematopoietic and bone-marrow stromal cells, antibody-mediated platelet destruction, reduced effect of thrombopoietin, increased circulating-platelet consumption via lung injury or multiple-organ failure, and immune complexes [8, 9] . Recent guidelines recommend steroids as first-line therapy for ITP associated with COVID-19. IVIG is recommended when an immediate rise in platelet count is required [10] . Administration of thrombopoietin-receptor agonists may be associated with increased risk of thrombosis and hepatobiliary biomarker abnormalities; that these agents be avoided in COVID-19 is recommended at present [5, 10] . As noted above, we refrained from administering corticosteroids for fear of potentiating infection via immunosuppression. Platelet counts promptly rose with IVIG treatment. Failure to develop anti-SARS-CoV-2 antibodies associated with immunochemotherapy (e.g., rituximab, corticosteroids) is described [11, 12] during follow-up [5] . As their follow-up period was only 50-60 days, whether persistent or chronic ITP developed is unknown. The authors point out, however, that COVID-19 may trigger a tolerance breakdown that could lead to persistent or chronic ITP. We believe that our patient is the first instance described of persistent ITP (>7 months follow-up) evolved from acute ITP associated with COVID-19. Thrombocytopaenia is a common comorbidity in COVID-19, likely with several aetiologies, among them ITP. As acute ITP triggered by events other than COVID-19 may progress to persistent or chronic ITP even after initial recovery in platelet count, we anticipate that more patients like ours will be encountered. Continuous and longterm monitoring of acute ITP associated with COVID-19 thus must be considered essential. Written informed consent was obtained from the patient for publication of the case report and accompanying images. The authors declare that there was no conflict of interest in carrying out this study. Immune thrombocytopenia preceded by asymptomatic COVID-19 infection Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group The ITP syndrome: pathogenic and clinical diversity Immune thrombocytopenic purpura in a patient with Covid-19 Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series Immune thrombocytopenia (ITP) in a pediatric patient positive for SARS-CoV-2 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Thrombocytopenia and its association with mortality in patients with COVID-19 Immune thrombocytopenia in a patient with COVID-19 Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma Immune thrombocytopenia purpura secondary to COVID-19